SCHEMBL7769258

SCHEMBL7769258

NC(=O)CNC(=O)Cc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.57
MEN1 O00255 1/20 0.57
HDAC8 Q9BY41 1/20 0.57
HDAC6 Q9UBN7 1/20 0.57
GAA P10253 2/20 0.56
HPGD P15428 2/20 0.56
CRHBP P24387 1/20 0.55
CRHR2 Q13324 1/20 0.55
ALDH1A1 P00352 4/20 0.54
ATM Q13315 1/20 0.54
LMNA P02545 1/20 0.54
EPHX2 P34913 1/20 0.53
MAPT P10636 2/20 0.53
RAB9A P51151 1/20 0.53
CNR1 P21554 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
TRPV1 Q8NER1 1/20 0.53
PKM P14618 1/20 0.53
KCNH2 Q12809 1/20 0.51
CA12 O43570 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenaceturic Acid SCHEMBL196523 0.84 ATM (0.62) KMT2AMEN1HDAC8HDAC6GAA
Phenaceturic Acid SCHEMBL14126285 0.84 ATM (0.62) KMT2AMEN1HDAC8HDAC6GAA
SCHEMBL1454495 0.82 MEN1 (0.63) KMT2AMEN1HDAC8HDAC6GAA
SCHEMBL7769503 0.81 HDAC2 (0.59) KMT2AMEN1HDAC8HDAC6HPGD
SCHEMBL29777267 0.81 GAA (0.58) GAAALDH1A1LMNAMAPTRAB9A
SCHEMBL5842518 0.81 ATM (0.65) KMT2AMEN1HDAC8HDAC6GAA
SCHEMBL11288698 0.81 ATM (0.59) KMT2AMEN1HDAC8HDAC6GAA
SCHEMBL21398985 0.81 KMT2A (0.57) KMT2AMEN1HDAC8HDAC6GAA
SCHEMBL7769256 0.81 KMT2A (0.57) KMT2AMEN1HDAC8HDAC6GAA
SCHEMBL5102819 0.81 KMT2A (0.57) KMT2AMEN1HDAC8HDAC6GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190201414-A1 INHIBITOR OF HEME DEGRADATION FOR USE TO IMPROVE ANTIBIOTIC TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTION THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) 2019-07-04 US disclosed
US-8450368-B2 Heme oxygenase inhibitors, screening methods for heme oxygenase inhibitors and methods of use of heme oxygenase inhibitors for antimicrobial therapy UNIVERSITY OF MARYLAND, BALTIMORE (US) 2013-05-28 US disclosed
US-8450368-B2 Heme oxygenase inhibitors, screening methods for heme oxygenase inhibitors and methods of use of heme oxygenase inhibitors for antimicrobial therapy UNIVERSITY OF MARYLAND, BALTIMORE (US) 2013-05-28 US disclosed
US-20100081661-A1 HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2010-04-01 US disclosed
US-20100081661-A1 HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2010-04-01 US disclosed
EP-0765879-B1 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests SANKYO CO (JP) 2001-02-14 EP disclosed
US-5861429-A MITICIDES AND ANTHELMINTICS SANKYO COMPANY, LIMITED (JP) 1999-01-19 US disclosed
EP-0765879-A1 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests SANKYO COMPANY LIMITED (JP) 1997-04-02 EP disclosed
EP-0006298-B1 ANTI-INFLAMMATORY 1-PHENYL-2-AMINOETHANOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF FOR TOPICAL USE, AND PROCESSES FOR THEIR MANUFACTURE IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081661-A1 HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY HMOX1, HMOX2, PPOX KMT2A 3310/4885MEN1 4396/4885HDAC8 2165/4885
US-20190201414-A1 INHIBITOR OF HEME DEGRADATION FOR USE TO IMPROVE ANTIBIOTIC TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTION HMOX1, HMOX2, PPOX KMT2A 3355/4885MEN1 2939/4885HDAC8 786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.